Kissei Pharmaceutical Co Ltd
TSE:4547
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (19.9), the stock would be worth ¥3 662.06 (16% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 23.8 | ¥4 375 |
0%
|
| Industry Average | 19.9 | ¥3 662.06 |
-16%
|
| Country Average | 20.9 | ¥3 837.74 |
-12%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Kissei Pharmaceutical Co Ltd
TSE:4547
|
181.4B JPY | 23.8 | 12.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 153.6 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 29.4 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 35.4 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 24.5 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 19.6 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 44.6 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 22 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 12 | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 20.9 |
| 70th Percentile | 32.2 |
| Max | 571 930 627.1 |
Other Multiples
Kissei Pharmaceutical Co Ltd
Glance View
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of pharmaceutical products and health foods. The company is headquartered in Matsumoto-Shi, Nagano-Ken and currently employs 1,863 full-time employees. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The firm is engaged in the collection and analysis of medicine development information, and the manufacture and sale of medicines. The company is also engaged in the purchase and sale of related materials, system development and information process work, construction contract work such as new construction, expansion and renovation of factories, laboratories and offices, the management of facility and equipment work, information collection and development support work, noodle manufacture and sale, and insurance agency business.
